| Title | Comparing the Efficacy and Safety of Intralesional Verapamil With Intralesional Triamcinolone Acetonide in Treatment of Hypertrophic Scars and Keloids: A Meta-Analysis of Randomized Controlled Trials |
| Authors | Wang, Pu Gu, Luosha Bi, Hongsen Wang, Qifei Qin, Zelian |
| Affiliation | Peking Univ, Dept Plast Surg, Hosp 3, 49 Huayuan North Rd, Beijing 100191, Peoples R China Zhengzhou Univ, Dept Plast Surg, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China |
| Keywords | INTERNATIONAL CLINICAL RECOMMENDATIONS CUSHINGS-SYNDROME INJECTIONS |
| Issue Date | Jun-2021 |
| Publisher | AESTHETIC SURGERY JOURNAL |
| Abstract | Background: Clinical treatment of hypertrophic scars (HSs) and keloids is often unsatisfactory. Intralesional injections of triamcinolone acetonide (TAC) and verapamil are widely used to treat HSs and keloids, but their efficacy and safety are controversial. Objectives: The aim of this study was to conduct a meta-analysis of the effectiveness and safety of verapamil and TAC in the treatment of HSs and keloids. Methods: Embase, Google Scholar, and PubMed were searched for randomized controlled trials (RCTs) from inception to February 2020. RCTs that evaluated treatment effects with the Vancouver Scar Scale or reported adverse effects were included. The continuous data and the dichotomous variables were analyzed as mean difference (MD) and relative risk (RR), respectively. Results: Seven RCTs (461 patients) were included. Compared with verapamil, TAC rapidly changed the height (MD = 0.07; P < 0.05) and Delta pliability (MD = 0.23; P < 0.05) after the first session, but subsequent treatments resulted in no significant differences in the Aheight, Delta pigmentation, Delta vascularity, and Delta pliability. Delta lthough total adverse effects (RR = 0.42; P= 0.1) were not significantly different, in the subgroup analysis the incidence of telangiectasia (RR = 0.04; P < 0.05) and skin atrophy (RR = 0.10; P< 0.05), but not pain (RR =1.27; P= 0.77), was significantly lower with verapamil than with TAC. Conclusions: Verapamil may be an effective substitute for TAC. Although total adverse effects did not change, the incidence of telangiectasia and skin atrophy was lower with verapamil than with TAC. |
| URI | http://hdl.handle.net/20.500.11897/618457 |
| ISSN | 1090-820X |
| DOI | 10.1093/asj/sjaa357 |
| Indexed | SCI(E) |
| Appears in Collections: | 第三医院 |
